Volastra Therapeutics Unveils Biomarker and Combo Data for KIF18A Inhibitors

Findings presented at AACR 2026 define a pan-cancer development strategy for the company's lead program.

Apr. 17, 2026 at 4:31pm

Got story updates? Submit your updates here. ›

An abstract X-ray-like image showing the intricate internal structure of a cancer cell, with glowing ghostly lines defining its key biological components.Volastra's KIF18A inhibitor program targets the complex machinery within cancer cells, offering a potential new therapeutic approach for diverse tumor types.NYC Today

Volastra Therapeutics, a clinical-stage oncology company, has announced new biomarker and combination data around its KIF18A inhibitor program at the American Association for Cancer Research (AACR) 2026 annual meeting. The data supports the development of KIF18A inhibitors across multiple tumor types, particularly in cancers with Rb pathway inactivation as indicated by p16 loss.

Why it matters

KIF18A is an emerging therapeutic target in oncology, and Volastra's findings could help identify the patient populations most likely to benefit from its KIF18A inhibitor program. Demonstrating the potential for combination with standard therapies is also key to expanding the clinical utility of this novel mechanism of action.

The details

Volastra's data shows that p16 loss, a marker of Rb pathway inactivation, can serve as a predictive biomarker for response to KIF18A inhibition. The company also presented evidence that KIF18A inhibitors can be effective both as monotherapies and in combination with standard cancer treatments across diverse tumor types.

  • The data was presented at the AACR 2026 annual meeting on April 17, 2026.

The players

Volastra Therapeutics

A clinical-stage oncology company pioneering therapies that target the Rb pathway and cell division machinery.

Got photos? Submit your photos here. ›

The takeaway

Volastra's findings highlight the potential of KIF18A inhibitors to address unmet needs across multiple cancer types, particularly those with Rb pathway alterations. The identification of p16 loss as a predictive biomarker could help guide patient selection for future clinical trials and ultimately bring this novel therapy to the patients most likely to benefit.